83 search results for: Atopic Dermatitis
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.
Coughing, Choking, Wheezing, Itching, Sneezing: Understanding the Connection Between Atopic Diseases Through a Case-Based Panel of Expert Nurse Practitioners
Join leading experts Miguel Lanz, Lakshi Aldredge, Angela Bretton, and Hilary Ugras in an engaging case-based discussion that explores the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases.
Real-World Effectiveness of Advanced Systemic Treatments in AD
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Marjolein de-Bruin Weller discusses the latest real-world data on the effects of advanced systemic treatments in patients with AD.
On the Surface: Restoring the Skin Barrier in Patients With AD
In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.
On the Surface: Restoring the Skin Barrier in Patients with AD
In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
KOL Video Interview – Dr Amy Paller
In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
Potential Biomarkers of Subclinical Control in AD Pathophysiology
Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025
Clinical Utility of Biomarkers in the Management of AD
Dr. Amy Paller discusses the clinical utility of TARC measurements in AD management at EADV 2025
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.
